STAT+: Genetically targeted drug from Kura Oncology induces remissions in adult leukemia patients
Kura Oncology presented early clinical trial results Saturday showing for the first time that its genetically targeted cancer drug can induce responses — including complete remission — in patients with advanced leukemia.
The data are preliminary, but suggest that the Kura drug, a once-daily pill called KO-539, could become an effective treatment for certain types of genetically defined acute myeloid leukemia (AML), a rapidly progressing bone marrow cancer that affects adults. The drug could also be used eventually to treat children with a different form of leukemia.
